Leap Therapeutics ( (LPTX) ) has released its Q3 earnings. Here is a breakdown of the information Leap Therapeutics presented to its investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Leap Therapeutics, now known as Cypherpunk Technologies Inc., is a biopharmaceutical company focused on developing antibody therapies for cancer treatment, with a recent strategic shift towards digital assets. The company recently reported its earnings for the quarter ending September 30, 2025, highlighting a significant name change and strategic pivot. Key financial metrics indicate a net loss of $3.3 million for the quarter, with operating expenses substantially reduced from the previous year. The company also completed a private placement, raising approximately $58.9 million to support its new focus on digital assets, specifically Zcash. Looking forward, Cypherpunk Technologies aims to leverage its recent capital raise to support both its ongoing biopharmaceutical operations and its new digital asset strategy, although it continues to face challenges in achieving profitability.